Abstract: Male breast cancer (MBC) is an uncommon malignant disease, with few large- scale clinical studies on its treatment and prognosis. To date, MBC management is based on the guidelines for female breast cancer (FBC). Although MBC and FBC share many similarities, a few differences still exist between them, specifically in their hormonal dependence and sensitivity to endocrine ther-apy. Therefore, the drug selection and medication time remain controversial in the endocrine therapy of MBC. Furthermore, other safe and effective measures for MBC patients who are resistant to traditional endocrine therapy deserve further study. This review summarizes recent major advances in MBC drug treatments, which intends to provide a reference for clinical treatment.